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Background: Echocardiography (echo) is a first line test to assess cardiac structure and function. It is not known if
cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) ordered during routine clinical
practice in selected patients can add additional prognostic information after routine echo. We assessed whether
CMR improves outcomes prediction after contemporaneous echo, which may have implications for efforts to
optimize processes of care, assess effectiveness, and allocate limited health care resources.
Methods and results: We prospectively enrolled 1044 consecutive patients referred for CMR. There were 38 deaths
and 3 cardiac transplants over a median follow-up of 1.0 years (IQR 0.4-1.5). We first reproduced previous survival
curve strata (presence of LGE and ejection fraction (EF) < 50%) for transplant free survival, to support generalizability
of any findings. Then, in a subset (n = 444) with contemporaneous echo (median 3 days apart, IQR 1–9), EF by echo
(assessed visually) or CMR were modestly correlated (R2 = 0.66, p < 0.001), and 30 deaths and 3 transplants occurred
over a median follow-up of 0.83 years (IQR 0.29-1.40). CMR EF predicted mortality better than echo EF in univariable
Cox models (Integrated Discrimination Improvement (IDI) 0.018, 95% CI 0.008-0.034; Net Reclassification
Improvement (NRI) 0.51, 95% CI 0.11-0.85). Finally, LGE further improved prediction beyond EF as determined by
hazard ratios, NRI, and IDI in all Cox models predicting mortality or transplant free survival, adjusting for age,
gender, wall motion, and EF.
Conclusions: Among those referred for CMR after echocardiography, CMR with LGE further improves risk
stratification of individuals at risk for death or death/cardiac transplant.
Keywords: Echocardiography, Cardiovascular magnetic resonance imaging, Late gadolinium enhancement, Ejection
fraction, Comparative effectivenessBackground
In routine clinical practice, it is not known whether car-
diovascular magnetic resonance (CMR) with left ven-
tricular ejection fraction (EF) measurement and tissue
characterization with late gadolinium enhancement* Correspondence: schelberteb@upmc.edu
1Department of Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, PA
2Cardiovascular Magnetic Resonance Center, UPMC, Pittsburgh, PA
Full list of author information is available at the end of the article
© 2013 Wong et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(LGE) can add any additional prognostic information
after 2-dimensional (2D) echocardiography. A clinical
question frequently posed to the CMR practitioner is the
following: “We already have an echocardiogram on this
patient; why do we need CMR?” Indeed, echocardiog-
raphy remains a first line test for evaluating patients
with known or suspected cardiac disease. Both echocar-
diography and CMR measure EF, a principal determinant
of risk that often governs medical, surgical, and device-
based therapies. CMR measures EF with 3-dimensionaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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employed by echocardiography [1] that are prone to
error related to suboptimal acoustic windows, off axis
images, foreshortening of the apex, endocardial dropout,
and confounding by wall motion abnormalities. [2,3] In
addition, while echocardiography detects prognostically
relevant wall motion abnormalities, [4] it cannot readily
characterize myocardial tissue composition. Myocardial
tissue composition characterized by late gadolinium en-
hancement (LGE), may improve outcomes prediction be-
yond EF. [5,6] Whether the potential advantages of
CMR regarding EF and LGE translate into added prog-
nostic ability after 2D echocardiography in selected
patient populations remains unproven.
Demonstrating prognostic contributions for a given
modality has considerable relevance from several
perspectives. Both patients and their physicians rely on
risk stratification to individualize care and optimize ther-
apy, and there is a need to understand the strengths and
limitations of imaging modalities. Comparisons of risk
assessment across modalities underlie efforts to assess
comparative effectiveness, optimize processes of care,
and allocate limited healthcare resources. If CMR with
LGE further refines risk stratification after echocardiog-
raphy in selected clinical populations, then CMR would
demonstrate a potential to improve care through
improved patient selection for interventions and more
efficient allocation of healthcare resources, despite the
higher expense of CMR upfront.
We studied only patients referred for clinical CMR
when deemed appropriate by their physicians. The specific
aim was to assess in a “real world” population the effective-
ness of CMR after echocardiography for the prediction of
1) all-cause mortality, or 2) cardiac transplant-free sur-
vival. Clinicians used these data for patient management,
and so they are inherently valid and legitimate parameters
worthy of further study. This study was not designed to
compare efficacy which has been previously reported.
[1,7,8] Thus, in this effectiveness study we prospectively
enrolled consecutive patients at the time of clinical CMR
referral at our institution and compiled echocardiography
and CMR data and “aged with our cohort”. [9] The
a priori intent of CMR and echocardiography data collec-
tion at time of CMR was to compare their ability to pre-
dict subsequent outcomes. First, we sought to verify
generalizability and confirm the findings of previous work
demonstrating that LGE adds incremental prognostic
value beyond EF by CMR in consecutive patients. [5]
Demonstrating generalizability, i.e., that CMR data are re-
producible across CMR centers, is useful to support any
subsequent claims of effectiveness. Then, in a subset with
contemporaneous echocardiography we tested the hy-
pothesis that EF assessed by CMR was a stronger pre-
dictor than EF assessed qualitatively. Finally, we tested thehypothesis that LGE would provide added predictive a-
bility beyond contemporaneous echocardiography EF as
determined by net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) from Cox
regression models predicting either death or transplant
free survival. Together, these data would support the po-
tential for added prognostic value of CMR after echocar-
diography in selected patients.
Methods
Patient population
After approval of the protocol from the Institutional Re-
view Board (IRB) which complied with the Declaration
of Helsinki, we prospectively recruited 1,044 consecutive
adult patients as they were referred for clinical CMR at
the University of Pittsburgh Medical Center (UPMC)
Cardiovascular Magnetic Resonance Center. Inclusion
criteria were the provision of verbal and written
informed consent, the ability to undergo a complete
contrast enhanced CMR scan which required a glomerular
filtration rate ≥30 mL/min/1.7 m2 and the absence of
other known contraindications to CMR scanning. This
group constituted the “reproducibility cohort” to assess the
reproducibility of the general findings of Cheong et al. [5].
In the sample, there was a subset of 451 individuals
who had contemporaneous echocardiography defined ar-
bitrarily as within 3 weeks of CMR (median 3 days, IQR
1–9 days). Patients with known or suspected stress-
induced (“takotsubo”) cardiomyopathy (n = 6), a condi-
tion where the EF can change rapidly, were excluded
from the cohort. Those with significantly large acute
myocardial infarctions or areas at risk, defined arbitrarily
but conservatively by peak troponin I levels >10 ng/mL
(0.1 ng/ml detection limit), were excluded (n = 1) if the
CMR scan was acquired more than 6 days apart, due to
concerns of confounding related to interval recovery of
stunned myocardium. Thus, 444 patients formed the
“echocardiography cohort.” CMR and echocardiograms
were acquired between September 2009 to August 2011.
We captured data elements that reflect routine clinical
practice in order to maximize generalizability. Demo-
graphic and comorbidity data were determined ac-
cording to the medical record and patient interview at
the time of CMR scanning. Data related to CMR or
echocardiography were recorded from the final clinical
reports. Study data were collected and managed using
REDCap (Research Electronic Data Capture) electronic
data capture tools hosted at the University of Pittsburgh.
[10] Vital status was ascertained by Social Security
Death Index queries and medical record review. To
identify individuals who received cardiac transplant, we
cross referenced our database with the University of
Pittsburgh Medical Center Cardiothoracic Transplanta-
tion Program’s Transplant Patient Management System,
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patients and is IRB approved.Echocardiography
All echocardiography exams except for 27 in the echo-
cardiography cohort and 129 in the reproducibility
cohort were acquired at the University of Pittsburgh
Medical Center with commercially available systems
read by 9 experienced echocardiographers. This echocar-
diography laboratory is accredited by the Inter Societal
Accreditation Commission - Echocardiography (ICAEL).
Nearly all EFs were assessed by visual estimation which
assigned values with discrete increments of Δ 5% from
0-75% with the exception of 7 subjects who had EF
measured by biplane Simpsons’ method. [2] Echocar-
diography contrast agents to improve endocardial border
definition were used in 37 subjects. The presence of re-
gional wall motion abnormalities which may be viewed
as a potential surrogate for myocardial infarction or LGE
was also recorded.CMR scans
Cine CMR
All patients underwent clinical CMR scans by dedicated
CMR technologists with a 1.5T Siemens Magnetom
Espree (Siemens Medical Solutions, Erlangen, Germany)
and a 32 channel phased array cardiovascular coil. The
exam included standard breath held segmented cine im-
aging with steady state free precession (SSFP). [11] Left
ventricular EF was measured without geometric
assumptions from short axis stacks of end diastolic and
end systolic cine frames (slices 6 mm thick, 4 mm apart,
30 frames per cardiac cycle). [11] In the presence of
arrhythmia or inability to breath hold (n = 38), we
employed non-segmented real-time cines over at least
4 seconds to identify end systole accurately with paral-
lel imaging factors of 4, and lower spatial resolution
(e.g., 96×192 matrix) to maximize temporal resolution
(e.g.., <75 msec/frame) without compromising the ability
to ascertain myocardial borders.
Late gadolinium enhancement
Late gadolinium enhancement (LGE) imaging [11] was
performed 10–20 minutes after a 0.2 mmol/kg intrave-
nous gadoteridol bolus (Prohance, Bracco Diagnostics,
Princeton, NJ). To optimize detection of grossly evident
LGE abnormality, we used phase sensitive inversion re-
covery pulse sequences to increase signal to noise ratios,
correct for surface coil intensity variation, and render
signal intensity proportional to T1 recovery; we used
both segmented gradient echo and single shot steady
state precession sequences [12,13].Statistical analysis
Categorical variables were summarized as percentages,
and continuous variables were summarized by their me-
dian and interquartile range. Nonparametric statistics were
employed for continuous variables after non-normality
was identified by visual inspection of distributions with
further confirmation by the Shapiro Wilk test. Since echo-
cardiography EFs were reported as small ranges of Δ 5%,
we used the midpoint of the range to compare to CMR
EFs which were discrete values. Statistical tests were two
sided, and p < 0.05 was considered significant. Chi square
tests compared associations between categorical variables,
and Wilcoxon rank sum tests compared associations
between continuous variables. Linear regression and
Bland-Altman analysis were performed to compare con-
temporaneous EF derived from echocardiography or
CMR. Survival analysis employed the log rank test or Cox
regression. Results were similar regardless of whether we
used the date of CMR as time zero for follow-up or the
date of echo as time zero for follow-up; we report the
latter since CMR mostly followed echocardiography.
The number of events limited the number of predictor
variables to permit roughly 10 events per predictor varia-
ble. Proportional hazards assumptions were verified by
Schoenfeld residuals and nonsignificant time interaction
terms for EF and LGE. There was no statistical interaction
in Cox regression models between LGE and EF regardless
of EF modality or endpoint (death or transplant free sur-
vival). We summarized the added predictive ability of
CMR data by computing the integrated discrimination
improvement (IDI) and net reclassification improvement
(NRI). The IDI measures the improvement of a new
model’s average sensitivity without sacrificing average spe-
cificity. The NRI measures the correctness of reclassifica-
tion of subjects based on their predicted probabilities of
events using the new model [14,15]:
NRI = (# events moving up − # events moving down)
/# events) + (# nonevents moving down
− # nonevents moving up)/# nonevents)
where events moving up or down are more or less likely,
respectively, to experience events as rated by the new
model. The NRI ranges from 0–2. Statistical analyses were
performed using SAS 9.2 (Cary, NC).
Results
Patient characteristics
The contemporaneous echocardiography cohort subset
was similar to the parent reproducibility cohort (Table 1).
In the echocardiography cohort, the median time diffe-
rence between echocardiography and CMR was 3 days
(IQR 1–9 days). Most CMR exams were ordered to
evaluate for scar in either the ischemic or nonischemic
Table 1 Patient characteristics
Variable Reproducibility
cohort
Contemporaneous
echocardiography
cohort
Frequency or
median
(interquartile range)
N = 1044
Frequency or
median
(interquartile range)
N = 444
Demographics
Age (years) 54 (42–65) 55 (44–65)
Female 41% 36%
White race 88% 88%
Black race 8.5% 8.1%
General Indication for
CMR exam
Known or suspected
cardiomyopathy
31% 36%
Possible coronary
disease (stress testing
or viability)
31% 30%
Vasodilator stress
testing
17% 17%
Evaluation for
arrhythmia substrate
21% 25%
Mass or thrombus 3% 3%
Hospitalization status
Inpatient 33% 36%
Comorbidity
Hypertension 45% 51%
Diabetes 17% 19%
Dyslipidemia 35% 37%
Current cigarette
smoking
15% 20%
Atrial fibrillation or
flutter
6% 8%
Body mass index (kg/
m2)
28.1 (24.4-33.4) 28.1 (24.1-33.2)
Obstructive coronary
artery disease (>70%
by angiography)
19% 20%
Prior coronary bypass 8% 8%
Prior percutaneous
coronary intervention
14% 15%
Prior heart failure
documented in medical
records
18% 22%
Laboratory, CMR, or
Echocardiography data
Glomerular filtration
rate (mL/min/1.73 m2)
82 (66–102) 81 (66–105)
Table 1 Patient characteristics (Continued)
Ejection fraction by
echocardiography (%) 58 (34–63) 58 (38–63)
Ejection fraction by
CMR (%)
58 (47–65) 55 (38–63)
Late gadolinium
enhancement (LGE)
42% 52%
Myocardial infarction by
LGE
19% 22%
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proximately 1 in 5 CMR scans employed vasodilator stress
testing. In 355 subjects (80%), echocardiography preceded
CMR. The final reports indicated that 76 of the 444 (17%)
echocardiograms were rated as technically difficult by the
interpreting physician.
Reproducibility of CMR survival data
In the larger reproducibility cohort, there were 38 deaths
and 3 cardiac transplants over a median follow-up of 1.0
years (IQR 0.4-1.5 years). Using CMR data only, we
obtained very similar relationships between the Kaplan-
Meier survival curve strata for transplant free survival
compared to the prior work of Cheong et al. [5] as
shown in Figure 1. Thus, simple risk stratification
schemes based on EF < 50% and LGE were reproducible
and generalized to our center.
Ejection fraction by echocardiography or CMR and
relation to mortality
While EF by echocardiography and CMR were
correlated and exhibited similar median EF measures
(58% vs. 55%), the correlation plot exhibited conside-
rable scatter (Figure 2), and CMR only explained 2/3 of
the variation in EF by echocardiography as shown by the
R2 of 0.66. The relation between CMR EF and echocar-
diography EF was not influenced by the time difference
between the two tests (p = 0.8), and there was no inter-
action with time between the two tests (p = 0.7). The
differences in EF did not vary as a function of the time
difference between the two tests (p = 0.9). Bland Altman
analysis revealed minimal bias (Figure 2). Importantly,
disagreement was most prominent in the middle of the
EF spectrum where clinical decision making relies most
heavily on accurate EF determination. When the EF
measures were placed into clinically meaningful catego-
ries (i.e., EF < 30% which indicates potential eligibility for
defibrillator implantation, or EF <50% which indicates
eligibility for medical therapy [16]) 102 individuals (23%)
were classified differently (Figure 2, panel C).
There were 30 deaths and 3 cardiac transplants in 444
patients in the echocardiography cohort over a median
follow-up of 0.83 years (IQR 0.29-1.40 years). In univariable
Figure 1 Generalizability is important for newer imaging modalities, and our survival data of consecutive patients stratified by
cardiovascular magnetic resonance (CMR) findings reproduced the results of others. Our data (n = 1044) in panel A yielded similar
relationships as initially described by Cheong et al., [5] reproduced in panel B (n = 857). Permission to reproduce the figure in panel B was
granted by the publisher (Wolters Kluwer Health).
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echocardiography or CMR were both related to mortality
(HR 1.05, 95% CI 1.02-1.07, and HR 1.05, 95% CI 1.03-
1.07, respectively for every 1% decrement in EF). Yet, the
association with all cause mortality or transplant free sur-
vival measured by the Wald χ2 was higher for EF measured
by CMR compared to EF measured by echocardiography
(21.5 versus 17.3 for death, respectively; 26.0 versus 20.1
for transplant free survival, respectively).
A univariable Cox regression model with CMR EF sig-
nificantly improved prediction of adverse events and sig-
nificantly reclassified patients at risk compared to a
univariable Cox regression model with echocardiography
EF (mortality: IDI 0.018, 95% CI 0.008-0.034; NRI 0.51,
95% CI 0.11-0.85; transplant free survival: IDI 0.026,
95% CI 0.013-0.045; NRI 0.61, 95% CI 0.25-0.94). These
data, shown graphically in Figure 3 indicate that CMR
EF stratifies risks of adverse events significantly better
than echocardiography EF, and that CMR EF reclassifies
individual patients culminating in improved prediction
of adverse events.
Added prognostic value of late gadolinium enhancement
In the echocardiography cohort, adding LGE data
(expressed as a binary variable) to Cox models containing
contemporaneous EF measured by echocardiography
improved risk stratification. Adjusting for age, EF mea-
sured by echocardiography, and regional wall motion
abnormalities detected by echocardiography, the presence
of LGE was strongly associated with adverse outcomes
(HR 5.44, 95% CI 1.62-18.3 for death; HR 5.71, 95% CI
1.71-19.1 for death or cardiac transplant) as shown in
Figure 4. CMR data in the form of LGE alone refines risk
stratification even with pre existing contemporaneous
echocardiography EF.LGE added also predictive ability beyond EF as
determined by the Net Reclassification Index (NRI) and
the Integrated Discrimination Improvement (IDI) in all
multivariable Cox regression models predicting all cause
mortality or predicting transplant free survival as shown
in Table 2. These data indicate that LGE significantly
improves the Cox regression model risk stratification for
death or transplant free survival beyond age, gender,
regional wall motion assessment by echocardiography,
and EF measurement, regardless of whether EF was
measured by CMR or echocardiography. Specifically,
LGE improves the discrimination of the models (IDI)
and improves the classification of individual patients
(NRI).
Discussion
This study supports the utility of CMR after contempo-
raneous echocardiography in selected patients. We de-
monstrate for the first time that CMR can refine
prediction of mortality and transplant free survival, even
when contemporaneous 2D echocardiography with EF
and wall motion assessment is available. Our data sug-
gest that CMR derived EF and 2D echocardiography
derived EF assessed visually are not always equivalent for
individual patients, not because of systematic bias, but
because of imprecision by echocardiography. Among
those referred for CMR, echocardiography derived EF
appeared to misclassify 23% of patients when EF is
divided into clinically relevant categories. Accordingly,
CMR derived EF was a significantly better predictor of
all cause mortality or transplant free survival in our co-
hort. Furthermore, beyond issues related to EF measure-
ment, LGE data in particular may significantly improve
the prediction of all cause mortality and transplant free
survival beyond preexisting echocardiography EF data
Figure 2 Ejection fraction (EF) measured by contemporaneous echocardiography and cardiovascular magnetic resonance (CMR)
correlate only moderately (panel A), and there is considerable scatter and misclassification. Bland-Altman analysis (panel B) reveals that
this scatter does not result from systematic bias. Importantly, most of scatter occurs in the 30%-50% range of the EF spectrum where clinical
decision making relies most heavily on EF measures as shown by the thin gray box in panel B. Of note, variation far exceeded the Δ 5%
increment used for EF reporting by echocardiography. In Panel C, despite similar median EF values and the absence of meaningful bias in the EF
measures of the population, the scatter exhibited by the individual differences in echocardiography and CMR EF measures culminate in 102
individuals (23%) of the sample being categorized differently (highlighted in bold font).
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diography data already exist, CMR data in selected
patients can provide more robust EF assessment and
additional information in the form of LGE that further
improves risk stratification beyond EF. Finally, we also
reproduced the relationships between EF/LGE survival
curve strata previously reported by others, [5] affirming
the apparent generalizability of CMR EF and LGE data.
Whether our findings extend to those not referred for
CMR is uncertain and beyond the scope of our study.
Nonetheless, our data suggest the potential for improved
risk stratification with CMR EF and LGE data in selected
patients. Indeed, CMR has been proposed as a clinically
robust technique to assess myocardial tissue and regional
and global function. LGE detection of key myocardial
changes such as necrosis or fibrosis has been previously
validated [17-19] and has been associated with improveddiagnosis of prognostically relevant, clinically unrecognized
myocardial infarction, [20-23] adverse outcomes, [5,20-24]
and limited functional recovery after revascularization [25]
or medical therapy. [26] Similarly, EF by CMR also has
been validated. [27] The precision of EF estimates by 2D
echocardiography may be improved by more liberal use of
echocardiography contrast agents [28] or the modified
Simpson’s rule. [2] Still, CMR provides 3D volumetric
assessment for EF measurement which is superior to 2D
biplane techniques and is more reproducible. [1,8] An
important observation from our study and others [28] was
that the discrepancies in EF measurement were largest in
the intermediate range as shown in the Bland-Altman
analysis from Figure 1. The intermediate range of EF (e.g.,
30-50%) is where clinical decision making is more nuanced
and possibly more reliant on accurate and precise EF
measurement.
Figure 3 Graphical depiction of the Net Reclassification Improvement (NRI) where univariable Cox regression models with
cardiovascular magnetic resonance (CMR) ejection fraction (EF) predicting all cause mortality (panel A) or death or cardiac transplant
(panel B) are compared to Cox regression models containing echocardiography (echo) EF. Since the reclassification improved using CMR
EF relative to echocardiography EF in both those with events and those without events, the NRI for all cause mortality and death/cardiac
transplant are 0.51 (includes rounding error; panel A) and 0.61 (panel B), respectively, after summing these net improvements for events
and nonevents.
Figure 4 Adjusted Kaplan Meier survival curves for all cause mortality (panel A) and death or cardiac transplantation (panel B)
according to late gadolinium enhancement (LGE) accounting for variation in age, ejection fraction by echocardiography, and regional
wall motion abnormalities detected by echocardiography.
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Table 2 Late gadolinium enhancement (LGE) added significant predictive ability for either death or transplant free
survival beyond ejection fraction (EF), age, regional wall motion by echocardiography and gender in Cox regression
models regardless of how EF was measured
Multivariable Cox regression model: Adjusted hazard
ratio for LGE
(95% CI)
NRI (95% CI) IDI (95% CI)
Outcome EF modality
Mortality CMR 3.84 (1.11-13.4) 0.61 (0.30-0.92) 0.017 (0.005, 0.028)
Mortality echocardiography 4.44 (1.30-15.2) 0.72 (0.40-0.98) 0.024 (0.008, 0.040)
Transplant free survival CMR 4.02 (1.16-13.9) 0.64 (0.35-0.93) 0.018 (0.005, 0.030)
Transplant free survival echocardiography 4.79 (1.41-16.3) 0.74 (0.46-0.99) 0.027 (0.009, 0.044)
All models stratified by gender and adjusted for age, regional wall motion abnormalities by echocardiography and ejection fraction (EF) by either
echocardiography or CMR. The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) reflect the added performance of the
model after LGE data are added.
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clinician’s decision to refer patients to CMR. When
clinicians chose to refer patients for CMR, it generally
yielded incremental prognostic information in our cohort.
Still, it is doubtful that CMR can ever accommodate the
volume of echocardiography laboratories which incur less
cost. Therefore, the challenge to the cardiology commu-
nity is how best to utilize CMR and echocardiography.
More data are needed to identify 1) whether the improved
risk stratification associated with CMR might improve
patient centered outcomes and cost effectiveness relative
to echocardiography-directed care through improved
matching of patients and interventions, and 2) whether
CMR may permit greater efficiency in the allocation of
limited healthcare resources. For example, CMR may have
value as a first line modality for those with known
decrements in EF, or susceptibility to poor acoustic
windows such as the obese or those with lung disease.
Preliminary knowledge from our study that CMR with
LGE has the potential to improve the classification of indi-
vidual patients at risk provides an important foundation
for justifying the significant costs and efforts associated
with implementing such research. Even if echocardio-
graphy yielded identical EF measures as CMR, possibly
with 3D techniques, LGE would still provide added prog-
nostic value as shown in Table 2. Novel CMR techniques
to quantify the extracellular volume fraction might refine
risk stratification even further [29-35].
Ultimately, these data may have implications for cli-
nical practice, for trials requiring risk assessment, and
for efforts to gauge comparative effectiveness and im-
prove processes of care. We speculate that for selected
patients, the improvements in risk stratification offered
by CMR (quantified in Table 2) may justify the higher
associated upfront costs and more complex infrastruc-
ture needed to support CMR practice. Conceptually,
CMR in selected patients could reduce downstream
costs and minimize adverse events through improved se-
lection of truly high risk patients for costly (relative to
CMR) and invasive procedures that also carry inherentrisk (e.g., defibrillator implantation). Ideally, overuse of
expensive and invasive procedures could be minimized by
identifying truly low risk individuals unlikely to benefit
who can avoid procedure-related risks, and underuse can
be minimized by identifying truly high risk individuals
likely to benefit despite the procedure-related risks. Fur-
ther study is undoubtedly needed to test these hypotheses
which remain unconfirmed.Limitations
Our study has limitations. First, as with all observational
studies, our sample has inherent selection/referral biases
so our results may not generalize to those not referred
for CMR. Nonetheless, we note that LGE is unique to
CMR, and no echocardiography report in our study
suggested sufficient uncertainty in EF determination to
warrant further EF determination by alternative imaging
modalities. Second, our results are obtained from a
single center with a dedicated CMR scanner and signifi-
cant underlying infrastructure committed to supporting
CMR, so results may not generalize to centers without
CMR expertise. Still, the availability of CMR is growing,
and we note that we could reproduce the CMR results
of others who demonstrated previously that LGE im-
proves risk stratification, suggesting that our center’s ex-
perience may not necessarily be unique. Finally, EF by
echocardiography was mostly estimated visually which
may represent a limitation. Yet, qualitative assessment
(often without echocardiography contrast) is widespread,
affirming the relevance of our data, and American Society
of Echocardiography (ASE) Guidelines [2] do not specify
optimal 2D echocardiography measurement techniques
for EF, i.e., qualitative versus modified biplane Simpson’s
method. While use of Simpson’s method or 3D echocardi-
ography may yield different results, ASE guidelines still
recommend cross checking quantitative attempts with
qualitative estimates, and others have reported that
Simpson’s method has inherent limitations compared to
3D tomographic techniques such as CMR [1-3,8].
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In selected patients referred for CMR in a real world set-
ting, CMR with LGE may improve risk stratification for
death or the combined endpoint of death/cardiac trans-
plantation after contemporaneous echocardiography. LGE
appears to provide additional prognostic ability beyond
ejection fraction. Also, visual EF measures by echocardiog-
raphy and CMR are not always equivalent. Individuals may
be classified differently by CMR after echocardiography,
and EF measurement by CMR may better predict subse-
quent mortality or transplant free survival compared to EF
measurement by echocardiography. The similarity of the
relationships between EF and LGE to that reported by
others [5] suggests our CMR data are generalizable. These
data may have implications for efforts to optimize care, as-
sess effectiveness, and allocate limited health care
resources. We hope this study will promote allocation of
additional resources needed to explore these issues further.
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